Oxford researchers have reportedly received promising news about their coronavirus vaccine

The University of Oxford's Jenner Institute made waves last week when U.K. Health Minister Matt Hancock announced a team is starting trials on a potential coronavirus vaccine of which there could be a million doses by September, which is, in vaccine terms, incredibly fast. There's still a long way to go before determining if the vaccine is viable, but The New York Times reports there's promising news that it may be both safe and effective.
Scientists at the National Institute of Health's Rocky Mountain Laboratory in Montana tested the Oxford vaccine on six rhesus macaques monkeys. The monkeys were exposed to heavy quantities of the coronavirus, an amount that had previously sickened other monkeys in the lab, before receiving a single dose of the vaccine. More than four weeks later all six monkeys were healthy, Dr. Vincent Munster, the researcher who conducted the test, told the Times. That doesn't mean it will work the same way in humans, but Munster noted the rhesus macaque is "pretty much the closest thing we have to humans," so the results are at least promising.
One thing that could hold trials back, however, is if other measures to curb the pandemic, such as social distancing, work too well, the Times reports. In order to get a real sense of a vaccine's efficacy, tests need to be conducted in places where the virus is spreading swiftly. Read more at The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Amazon's 'James Bond' deal could mean a new future for 007
In the Spotlight The franchise was previously owned by the Broccoli family
By Justin Klawans, The Week US Published
-
Why are Republicans suddenly panicking about DOGE?
TODAY'S BIG QUESTION As Trump and Musk take a chainsaw to the federal government, a growing number of Republicans worry that the massive cuts are hitting a little too close to home
By Rafi Schwartz, The Week US Published
-
What is JD Vance's Net Worth?
In Depth The vice president is rich, but not nearly as wealthy as his boss and many of his boss' appointees
By David Faris Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published